In my practice, I choose the most effective treatment across the board to control blood sugar and reduce the risk for complications from renal, cardiovascular, and other common comorbidities.
For patients with T2D and cardiovascular disease, we are fortunate to have several GLP-1 receptor agonists with an indication for reducing the risk of major adverse cardiovascular events. Here’s my approach to choosing among them.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.